Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Cell death"" wg kryterium: Temat


Tytuł:
银屑病患者血清 sPD-1、C 反应蛋白及 LRG1 的表达与 病情严重程度的关系.
Autorzy:
郑智敏
王 静
于丽丽
于凌艳
梁晓光
Pokaż więcej
Alternatywny tytuł:
Relationship between the Expression of sPD-1, C-reactive Protein and LRG1 in Serum and the Severity of Psoriasis.
Źródło:
Progress in Modern Biomedicine. Nov2023, Vol. 23 Issue 21, p4158-4162. 5p.
Czasopismo naukowe
Tytuł:
健脾除痰解毒方通过PD-1/PD-L1 通路平衡Th1/Th2 漂移而增强Lewis 肺癌小鼠免疫功能.
Autorzy:
詹雪
冯诗函
杨倩
谭琪
张佳艳
王淑美
Pokaż więcej
Alternatywny tytuł:
Jianpi-Chutan-Jiedu Formula enhances immune function in mice with Lewis lung carcinoma by modulating PD-1/PD-L1 pathway and shifting Th1/Th2 balance.
Źródło:
Chinese Journal of Pathophysiology. Oct2023, Vol. 39 Issue 10, p1823-1831. 9p.
Czasopismo naukowe
Tytuł:
[Efficacy of adjuvant programmed cell death 1 (PD-1) monoclonal antibody immunotherapy in Chinese patients with resected stage Ⅱ-Ⅲ melanoma].
Autorzy:
Ren ZG; Department of Orthopedics, Shanghai Electric Power Hospital, Shanghai 200050, China.
Xu Y; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Hua ZZ; Department of Orthopedics, Shanghai Electric Power Hospital, Shanghai 200050, China.
Mo ZY; Department of Orthopedics, Shanghai Electric Power Hospital, Shanghai 200050, China.
Wang LW; Department of Orthopedics, Shanghai Electric Power Hospital, Shanghai 200050, China.
Shi GB; Department of Orthopedics, Shanghai Electric Power Hospital, Shanghai 200050, China.
Liu WL; Department of Orthopedics, Shanghai Electric Power Hospital, Shanghai 200050, China.
Sun W; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Zheng BQ; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Wang CM; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Jin YJ; Department of Orthopedics, Shanghai Electric Power Hospital, Shanghai 200050, China.
Chen Y; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2023 Nov 23; Vol. 45 (11), pp. 973-980.
Typ publikacji:
Observational Study; English Abstract; Journal Article
MeSH Terms:
Melanoma*/drug therapy
Melanoma*/pathology
Skin Neoplasms*/drug therapy
Skin Neoplasms*/pathology
Humans ; Antibodies, Monoclonal/therapeutic use ; Apoptosis ; China ; Disease-Free Survival ; East Asian People ; Immunotherapy ; Interferon-alpha/therapeutic use ; Lymphatic Metastasis ; Programmed Cell Death 1 Receptor/therapeutic use ; Melanoma, Cutaneous Malignant
Czasopismo naukowe
Tytuł:
功能化氧化石墨烯携带PD-L1 siRNA抑制肝癌 细胞的恶性生物学行为.
Autorzy:
李志伟
单丽红
刘曦冉
闵 洋
丁小凤
李立民
Pokaż więcej
Alternatywny tytuł:
Functionalized Graphene Oxide Carrying PD-L1 siRNA Inhibits the Malignant Biological Behaviors of Liver Cancer Cells.
Źródło:
Journal of Laser Biology / Acta Laser Biology Sinica. Aug2023, Vol. 32 Issue 4, p345-352. 8p.
Czasopismo naukowe
Tytuł:
基于 Bcl-2/CytC 探究槲皮素对肝硬化大鼠微循环及肝脏病变的影响.
Autorzy:
蔡景治
郑 扬
仲伟明
刘 波
Pokaż więcej
Alternatywny tytuł:
To Investigate the Effects of Quercetin on Microcirculation and Liver Lesions in Cirrhotic Rats Based on Bcl-2/CytC Regulatory Network.
Źródło:
Progress in Modern Biomedicine. Mar2023, Vol. 23 Issue 5, p818-823. 6p.
Czasopismo naukowe
Tytuł:
非小细胞肺癌组织中 NF-κB p65 与 PD-1, PD-L1 表达的相关性 以及对预后的预测价值分析.
Autorzy:
王 星
李小忠
宁 峰
董玉婷
江 静
Pokaż więcej
Alternatywny tytuł:
Analysis of Correlation between NF-κB p65 and PD-1, PD-L1 in Non-small Cell Lung Cancer Tissues and Its Prognostic Value.
Źródło:
Progress in Modern Biomedicine. Feb2023, Vol. 23 Issue 3, p313-317. 5p.
Czasopismo naukowe
Tytuł:
[Clinical analysis of liver dysfunction induced by SHR-1210 alone or combined with apatinib and chemotherapy in patients with advanced esophageal squamous cell carcinoma].
Autorzy:
Qi L; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhang B; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Liu Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Mu L; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Li Q; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Wang X; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Xu JP; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Wang XY; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Huang J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2023 Mar 23; Vol. 45 (3), pp. 259-264.
Typ publikacji:
English Abstract; Journal Article
MeSH Terms:
Esophageal Squamous Cell Carcinoma*/drug therapy
Esophageal Neoplasms*/drug therapy
Esophageal Neoplasms*/pathology
Liver Diseases*/etiology
Humans ; Prospective Studies ; Programmed Cell Death 1 Receptor/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Tytuł:
[Efficacy and safety of neoadjuvant chemotherapy combined with PD-1 antibody for esophageal squamous cell carcinoma in the real world].
Autorzy:
Wu PY; The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
Wang T; Departement of General Thoracic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
Chen BJ; Departement of General Thoracic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
Shi MK; Departement of General Thoracic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
Huang B; The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
Wu ND; The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
Qi L; The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
Chang XF; The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
Wang LF; The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
Liu BR; The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
Ren W; The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2023 Feb 23; Vol. 45 (2), pp. 170-174.
Typ publikacji:
English Abstract; Journal Article
MeSH Terms:
Carcinoma, Squamous Cell*/drug therapy
Carcinoma, Squamous Cell*/surgery
Esophageal Neoplasms*/drug therapy
Esophageal Neoplasms*/surgery
Esophageal Squamous Cell Carcinoma*/drug therapy
Humans ; Antibodies/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; Cisplatin ; Immune Checkpoint Inhibitors/therapeutic use ; Neoadjuvant Therapy ; Programmed Cell Death 1 Receptor/therapeutic use ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł:
卡瑞利珠单抗联合安罗替尼治疗晚期胃癌的疗效 及对近期预后的影响.
Autorzy:
沈 旺
杜雲雲
罗明莹
肖志季
彭黎铭
Pokaż więcej
Alternatywny tytuł:
Efficacy of Carrelizumab Combined with Amlotinib in the Treatment of Advanced Gastric Cancer and Its Effect on Short-Term Prognosis.
Źródło:
Evaluation & Analysis of Drug-Use in Hospitals of China. 2022, Vol. 22 Issue 1, p32-42. 7p.
Czasopismo naukowe
Tytuł:
[CXCL5 inhibits tumor immune of lung cancer via modulating PD1/PD-L1 signaling].
Autorzy:
Xie XH; Department of Oncology, the First Affiliated Hospital of Henan University, Kaifeng 475000, China.
Wang YJ; Department of Gynaecology and Obstetrics, the First Affiliated Hospital of Henan University, Kaifeng 475000, China.
Lei W; Department of Ultrasonography, the First Affiliated Hospital of Henan University, Kaifeng 475000, China.
Gao HJ; Department of Oncology, the First Affiliated Hospital of Henan University, Kaifeng 475000, China.
Duan YJ; Department of Oncology, the First Affiliated Hospital of Henan University, Kaifeng 475000, China.
Hou X; Department of Oncology, the First Affiliated Hospital of Henan University, Kaifeng 475000, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2022 May 23; Vol. 44 (5), pp. 382-388.
Typ publikacji:
Journal Article
MeSH Terms:
B7-H1 Antigen*/metabolism
Chemokine CXCL5*/metabolism
Lung Neoplasms*/immunology
Lung Neoplasms*/metabolism
Lung Neoplasms*/pathology
Animals ; CD8-Positive T-Lymphocytes ; Humans ; Mice ; Mice, Inbred C57BL ; Programmed Cell Death 1 Receptor/metabolism
Czasopismo naukowe
Tytuł:
[Progress of PD-1/PD-L1 inhibitors in the treatment of small-cell lung cancer].
Autorzy:
Zhang SY; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Wang Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2021 Jan 23; Vol. 43 (1), pp. 98-103.
Typ publikacji:
Journal Article
MeSH Terms:
Lung Neoplasms*/drug therapy
Small Cell Lung Carcinoma*/drug therapy
B7-H1 Antigen/therapeutic use ; Humans ; Immune Checkpoint Inhibitors ; Immunotherapy ; Neoplasm Recurrence, Local ; Programmed Cell Death 1 Receptor/therapeutic use
Czasopismo naukowe
Tytuł:
miR-335-5p 靶向程序化细胞死亡基因 5 对骨关节炎软骨细胞增殖、 凋亡的影响.
Autorzy:
张云青
王 健
阳春华
李 聪
Pokaż więcej
Alternatywny tytuł:
Effects of miR-335-5p on proliferation and apoptosis of osteoarthritic chondrocytes by targeting programmed cell death 5.
Źródło:
Chinese Journal of Tissue Engineering Research / Zhongguo Zuzhi Gongcheng Yanjiu. 5/18/2021, Vol. 25 Issue 14, p2142-2147. 6p.
Czasopismo naukowe
Tytuł:
腰突颗粒通过调控 miR-221 表达干预髓核细胞的增殖与凋亡.
Autorzy:
何升华
付远飞
蓝志明
孙志涛
赖居易
冯华龙
郭子宾
李 盖
Pokaż więcej
Alternatywny tytuł:
Yaotu Granule deals with the proliferation and apoptosis of nucleus pulposus cells via regulating the expression of microRNA-221.
Źródło:
Chinese Journal of Tissue Engineering Research / Zhongguo Zuzhi Gongcheng Yanjiu. 5/18/2021, Vol. 25 Issue 14, p2177-2182. 6p.
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies